m6A-centered Drug Response Information

General Information of the Drug (ID: M6ADRUG0069)
Name
ML162
Synonyms
ML162; 2-[(chloroacetyl)(3-chloro-4-methoxyphenyl)amino]-N-(2-phenylethyl)-2-thien-2-ylacetamide; ML-162; SMR000206941; MLS000583955; 2-(3-chloro-N-(2-chloroacetyl)-4-methoxyanilino)-N-(2-phenylethyl)-2-thiophen-2-ylacetamide; alpha-[(2-chloroacetyl)(3-chloro-4-methoxyphenyl)amino]-N-(2-phenylethyl)-2-thiopheneacetamide; BRD5421; BRD-5421; 2-(3-chloro-N-(2-chloro-1-oxoethyl)-4-methoxyanilino)-N-(2-phenylethyl)-2-thiophen-2-ylacetamide; MLS002588779; MLS002703080; CHEMBL1499544; SCHEMBL15428380; BDBM66431; CHEBI:91657; cid_3689413; AOB1514; HMS2544O20; HMS3874J03; EX-A4946; s4452; AKOS024440074; AS-16657; HY-100002; CS-0017910; SR-01000705401; SR-01000705401-2; BRD-A36275421-001-04-6; BRD-A36275421-001-06-1; BRD-A36275421-001-09-5; BRD-A36275421-001-11-1; BRD-A36275421-001-13-7; BRD-A36275421-001-14-5; BRD-A36275421-001-15-2; Q27163480; 2-(3-chloro-N-(2-chloroacetyl)-4-methoxy-anilino)-N-phenethyl-2-(2-thienyl)acetamide; 2-[3-chloro(2-chloroacetyl)-4-methoxyanilino]-N-phenethyl-2-(2-thienyl)acetamide; 2-[Chloroacetyl(3-chloro-4-methoxyphenyl)amino]-N-phenethyl-2-(2-thienyl)acetamide; 2-[2-chloranylethanoyl-(3-chloranyl-4-methoxy-phenyl)amino]-N-(2-phenylethyl)-2-thiophen-2-yl-ethanamide
    Click to Show/Hide
Status Investigative [1]
Structure
Formula
C23H22Cl2N2O3S
InChI
InChI=1S/C23H22Cl2N2O3S/c1-30-19-10-9-17(14-18(19)25)27(21(28)15-24)22(20-8-5-13-31-20)23(29)26-12-11-16-6-3-2-4-7-16/h2-10,13-14,22H,11-12,15H2,1H3,(H,26,29)
InChIKey
UNVKYJSNMVDZJE-UHFFFAOYSA-N
PubChem CID
3689413
Full List of m6A Targets Related to This Drug
CDR1 antisense RNA (CDR1-AS)
 Target Info 
In total 1 item(s) under this target gene
Experiment 1 Reporting the m6A-centered Drug Response by This Target Gene [2]
Response Summary CDR1 antisense RNA (CDR1-AS) a regulator of miR-7, as a hallmark of melanoma progression. CDR1as depletion results from epigenetic silencing of LINC00632, its originating long non-coding RNA (lncRNA) and promotes invasion in vitro and metastasis in vivo through a miR-7-independent, IGF2BP3-mediated mechanism. IGF2BP3 interacts with CDR1as and mediates invasion induced by CDR1as depletion. CDR1asHigh melanoma cell lines were strikingly more sensitive to three different GPX4 inhibitors, which are known to elicit ferroptotic cell death.
Responsed Disease Melanoma ICD-11: 2C30
 Disease Info 
Target Regulator Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) READER
 Regulator Info 
Target Regulation Up regulation
In-vitro Model 451Lu Cutaneous melanoma Homo sapiens CVCL_6357
501-mel Melanoma Homo sapiens CVCL_4633
A-375 Amelanotic melanoma Homo sapiens CVCL_0132
SK-MEL-147 Melanoma Homo sapiens CVCL_3876
SK-MEL-173 Melanoma Homo sapiens CVCL_6090
SK-MEL-2 Melanoma Homo sapiens CVCL_0069
SK-MEL-239 Melanoma Homo sapiens CVCL_6122
SK-MEL-28 Cutaneous melanoma Homo sapiens CVCL_0526
WM115 Melanoma Homo sapiens CVCL_0040
WM1361A Cutaneous melanoma Homo sapiens CVCL_6788
WM1552C Cutaneous melanoma Homo sapiens CVCL_6472
WM266-4 Melanoma Homo sapiens CVCL_2765
WM278 Cutaneous melanoma Homo sapiens CVCL_6473
WM35 Melanoma Homo sapiens CVCL_0580
WM793b (Immunodeficient mice Cell Type melanocyte)
WM902B Melanoma Homo sapiens CVCL_6807
In-vivo Model 4-6 weeks old NOD/Shi-scid/IL-2Rgamma null (NOD.Cg-PrkdcscidIl2rgtm1Wjl/SzJ (NSG)) mice (female).
References
Ref 1 Nrf2 inhibition reverses resistance to GPX4 inhibitor-induced ferroptosis in head and neck cancer. Free Radic Biol Med. 2018 Dec;129:454-462. doi: 10.1016/j.freeradbiomed.2018.10.426. Epub 2018 Oct 16.
Ref 2 Epigenetic Silencing of CDR1as Drives IGF2BP3-Mediated Melanoma Invasion and Metastasis. Cancer Cell. 2020 Jan 13;37(1):55-70.e15. doi: 10.1016/j.ccell.2019.12.007.